Co-Development of PARP-1 Targeted Radiopharmaceuticals
Digmbio signed a co-development agreement with BIK Therapeutics for DM5167-based radiopharmaceuticals utilizing radioisotope labeling and drug delivery technologies to PARP1 selective inhibitor.
May 2026
DM5167 Phase 2 IND Clearance
U.S. FDA-cleared Phase 2 clinical development targeting rare cancer.
Selected for the 2026 Investment Readiness Support Program
Supported by KHIDI(Korea Health Industry Development Institute) and ScaleUp Partners to strengthen investment readiness and fundraising capabilities.
April 2026
Selected for the '2026 DIPS 1000+' Initiative (Bio Sector)
Selected for the ‘2026 DIPS 1000+’ initiative in the Bio sector by the Ministry of SMEs and Startups and the Korea Institute of Toxicology (KIT).
March 2026
Co-Development of Next-Generation PARP1 PROTAC-Based Cancer Therapeutics
DigmBio and AxcesoBiopharma have entered into a joint research agreement to advance the development of next-generation PARP1 PROTAC-based cancer therapeutics.
May 2025
Selected for the Ministry of SMEs and Startups' '2025 Baby Unicorn' Program
Named to the prestigious '2025 Baby Unicorn 50' cohort within the Bio & Healthcare division.
December 2025
Selected for the 2nd 2025 KDDF National Drug Development Program for Parkinson's Disease
Selected for the KDDF’s 2025 National Drug Development Program, aiming to establish a stronger drug R&D ecosystem.
Opening of DigmBio's Gwanggyo (Suwon) R&D Center
Expanded its research footprint with a new Gwanggyo facility dedicated to advanced drug discovery and development.
March 2025
Completed Series A Financing
Raised KRW 12 billion in Series A financing, drawing strategic participation from prominent investorswith participation from like Partners Investment, Meritz Securities, Samho Green Investment, Industrial Bank of Korea, Medytox Venture Investment, Cornerstone Investment Partners, and Myriad Life Sciences.
January 2025
Selected for the 2nd 2024 KDDF Phase 1 Clinical Trial Support Program
Awarded clinical development funding for DM5167, a second-generation PARP1-selective inhibitor, enabling the initiation of Phase 1 trials to evaluate safety, tolerability, and MTD.
March 2024
DM5167 IND Approved
Cancer therapy, DM5167, a second-generation PARP1 selective inhibitor, has received approval for IND application for a phase 1 trial in Korea
May 2023
Parkinson's Disease Therapy Selected for Grant
Awarded a grant from the Korea Drug Development Fund to bolster its research and development efforts targeting disease.
April 2023
DM5167 Introduced in AACR 2023
Digmbio has released a poster presentation titled DM5167: A Novel Selective PARP1 Inhibitor Significantly Reduces Triple Negative Breast Cancers during AACR 2023.
January 2022
A Cancer Drug Candidate In-Licensed
Acquired the rights to a cancer drug candidate, a PARP1 inhibitor, through in-licensing from Chung Nam Univ. and Kukje Pharma.
August 2021
DM5167 Patent Registered
The DM5167 patent for a pharmaceutical composition targeting PARP1-related diseases was registered in Korea in August 2021. It has been issued across 14 global regions.
April 2021
National Research Grant for Alzheimer's Disease
DigmBio Alzheimer's disease project received a grant from Korea Dementia Research Center sponsored by the Ministry of Science & ICT and the Ministry of Health & Welfare.
December 2020
New Facilities Opened
New Headquarters and lab opened in Pangyo Valley, Korea.
September 2020
Alzheimer's Disease Research Started.
DigmBio has initiated a collaborative effort with Daegu Catholic University for their Alzheimer's disease program.
April 2020
DigmBio Incorporated
DigmBio was founded, deriving its corporate name from the concept of paradigm-shifting biotechnology.
May 2026
DM5167 Phase 2 IND Clearance
U.S. FDA-cleared Phase 2 clinical development targeting rare cancer.
